Light To Guide Our Feet
Light To Guide Our Feet

Menu

Collapse

Search Result

Collapse

Announcement

Collapse
No announcement yet.

What's Going On

Collapse

There are currently 83 users online. 6 members and 77 guests.

Most users ever online was 3,930 at 07:07 PM on 04-20-2019.

1 result in 0.0036 seconds.
Keywords
Members
Tags
COVID-1 x
  •  

  • NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin plus Remdesivir to Treat COVID-19 Begins

    National Institutes of Health Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin plus Remdesivir to Treat COVID-19 Begins | site |


    Editor's note: Please note that this article was published on October 8, 2020

    (October 8, 2020) - - On October 8, 2020, the National Institutes of Health (NIH) published the following information:

    A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. The National


    Graphic courtesy NIH/NIAID
    Institute of Allergy...
    See more | Go to post

Menu

Collapse

Trending

Collapse

  • Staff Reporter 1
    NIH Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin plus Remdesivir to Treat COVID-19 Begins
    by Staff Reporter 1
    National Institutes of Health Clinical Trial Testing Hyperimmune Intravenous Immunoglobulin plus Remdesivir to Treat COVID-19 Begins | site |


    Editor's note: Please note that this article was published on October 8, 2020

    (October 8, 2020) - - On October 8, 2020, the National Institutes of Health (NIH) published the following information:

    A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. The National


    Graphic courtesy NIH/NIAID
    Institute of Allergy...
    10-15-2020, 03:03 AM

Menu

Collapse

Menu

Collapse

Working...
X